19 Sep 2023 Successful Completion of ALS-6000-101 Sixth Dose Escalation and Clinical Update Investors | Therapeutics
21 Jun 2023 Successful Completion of Fifth Dose Escalation in AVA6000 Phase 1 Clinical Study Investors | Therapeutics
05 Jun 2023 Avacta Achieves Second Milestone in AffyXell Joint Venture Triggering Increased Equity Stake Investors | Therapeutics
27 Apr 2023 First Patient Dosed in the US in Avacta’s AVA6000 Phase 1 Clinical Study Investors | Therapeutics
17 Apr 2023 Avacta Presents AVA3996 Pre-clinical Data at the American Association for Cancer Research Meeting Investors | Therapeutics
06 Apr 2023 Avacta Opens First Two US Clinical Investigator Sites for AVA6000 Phase 1 Clinical Study Investors | Therapeutics
05 Apr 2023 First Patient Dosed in Fifth Cohort of AVA6000 Phase Ia Dose Escalation Study Investors | Therapeutics
27 Mar 2023 Avacta to present pre-clinical data on AVA3996 at the American Association for Cancer Research Annual Meeting Investors | Therapeutics